1_edited.jpg

PIPELINES

Nanozyme

CX213

molecular-structure-abstract-science-bac

CX213 can be applied to acute inflammatory damage, and can simultaneously scavenge various kinds of reactive oxygen species by using inorganic, oxide-based, nanocatalytic functions. Clinical applicability has been verified through vigorous experimentation.

그림3.png
그림7.png

High potency

One CX213 particle has multiple reaction centers, which can all scavenge various reactive oxygen species. Additionally, the excellent surface area to volume ratio, which is characteristic of nanoparticles, ensures a maximum therapeutic effect with a low volume of particles.

Adaptability

그림16.png
그림2.png
그림2.png
그림4.png

Safety

Several studies have shown that biocompatibility increases by coating the surface of CX213 with a polymeric compound. CX213 has a large therapeutic index: the toxic dose is more than 100 times the therapeutic dose.

그림17.png

Expandability

Traditional antioxidants can only scavenge certain types of reactive oxygen species, but CX213 can scavenge all known reactive oxygen species.

CX213 could lead to an expansion of indicators for a variety of diseases in which the pathophysiology is related to reactive oxygen species.

이미지 제공: JJ Ying

CX213 for treatment of acute inflammatory injury

In acute inflammatory injury, excessive reactive oxygen species (ROS) are produced.

It is too large amount to be eliminated by an endogenous antioxidant in the body, resulting severe acute inflammatory responses.

CGMEDI_ _세닉스바이오테크_ROS_v6(뇌,텍스트삭제)-01.png

Macrophage

activation

Leukocyte

infiltration

Damage of brain cells and tissue

Acute

inflammatory cattle

CX213 for treatment of subarachnoid hemorrhage

그림19.png

Main target disease: SAH

SAH is a subtype of stroke that causes bleeding due to damaged large arteries on the surface of the brain, mostly caused by a rupture of intracranial aneurysms.

The acute inflammatory response is triggered by reactive oxygen species caused by toxic component of extravasated blood, resulting severe neurological deficit or death.

Up to 10% of patients die even before arriving at the hospital, and 25% of patients die within 24 hours. Despite the best medical treatment, the 6-month mortality rate reaches up to 50%.

Current clinical guidelines recommend surgery or endovascular treatment for repair of ruptured aneurysms, but this only prevents further bleeding and does not solve widespread acute inflammation caused by extravasated blood, which leads to high mortality.

이미지 제공: Bill Oxford

The efficacy of CX213 was investigated by applying a randomized, investigator-blinded clinical trial design in the subarachnoid hemorrhage animal model. The CX213-treated group significantly increased survival rate as 3 times more than the control group.

그림20.png

More than

3 Times

Identification of survival rate

Cenyx Biotech inc. and one other, “New cerium oxide nanocomposite and its use”, 10-2020-0036974, 2020.3.26

3 times higher survival rate